免疫功能低下者接种变异株适配新冠疫苗加强针的3.5年免疫应答随访
本研究对24名慢性肾病或风湿病患者随访长达3.5年,评估连续接种原始/BA.4-5和JN.1变异株适配加强针前后体液与细胞免疫应答。BA.4-5加强针将不同变异株中和抗体应答率提升至43%-100%,JN.1加强针使JN.1中和抗体水平升高5.3倍、应答率达80%-100%;T细胞应答跨变异株可检出且与健康对照相当,但额外加强未进一步增强T细胞应答。
要点
- 变异株适配加强针可拓宽对奥密克戎亚型的中和活性。
- JN.1加强针使JN.1中和抗体水平升高5.3倍。
- 额外加强未进一步增强T细胞应答,但T细胞应答保持稳定。
核心结论
- 连续接种变异株适配新冠加强针可拓宽对奥密克戎亚型的中和活性。
- 额外加强针未使抗体水平超越先前剂量,也未进一步增强T细胞应答。
- T细胞应答保持稳定,提示尽管抗体水平低或衰减,仍可能存在持久细胞保护。
研究设计与样本
- 前瞻性随访研究,随访长达3.5年。
- 纳入24名免疫功能低下个体:慢性肾病10例、风湿病14例,疫苗接种和感染史多样。
- 评估原始/BA.4-5和JN.1变异株适配加强针接种前后体液和细胞免疫应答。
- 对照为13名已接种三剂原始疫苗的健康人。
主要发现
- BA.4-5加强针后中和抗体应答率:野生型90-100%、BA.5.1 80-100%、XBB.1.5 71-86%、JN.1 43-71%。
- JN.1加强针使针对JN.1的中和抗体水平升高5.3倍,应答率达80-100%。
- 所有变异株均可检测到T细胞应答,且与健康对照相当,即使在抗体水平较低或衰减的患者中也是如此。
- 额外加强针未进一步增强T细胞应答。
临床怎么用
- 对免疫功能低下个体,可考虑连续接种变异株适配加强针以拓宽中和抗体覆盖。
- 抗体水平低或衰减时,T细胞应答可能仍提供保护,不应仅凭抗体水平评估免疫状态。
局限性
- 样本量小(共24例免疫功能低下个体和13例健康对照)。
- 随访期间疫苗接种和感染史多样,可能影响免疫应答比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunocompromised individuals mount suboptimal responses to COVID-19 vaccines, necessitating additional booster dose recommendations. However, long-term data on humoral and T-cell mediated immunity following sequential doses in this population remain limited. METHODS: We followed 24 individuals living with chronic kidney disease (n = 10) or rheumatological disease (n = 14) with diverse COVID-19 vaccination and infection history for up to 3.5 years. We assessed humoral and cellular immune responses before and after sequential original/BA.4-5 and JN.1 variant-adapted booster doses. Binding and neutralizing antibodies (NAbs) and T-cell responses to wild-type, BA.5, XBB.1.5, and JN.1 were analyzed before and one month after vaccination and compared to healthy controls (n = 13) who had received three doses of the original vaccine. RESULTS: The BA.4-5 booster vaccination increased NAb response rates to 90-100% (wild-type), 80-100% (BA.5.1), 71-86% (XBB.1.5), and 43-71% (JN.1). The JN.1 booster further increased NAb levels against JN.1 by 5.3-fold and raised response rates to 80-100%. T-cell responses were detected across all variants, and remained comparable to healthy controls, even in patients with lower or waning antibody levels. However, additional booster doses did not further augment T-cell responses. CONCLUSIONS: Sequential administration of variant-adapted COVID-19 boosters broadened neutralizing activity against Omicron subvariants, although it did not further elevate antibody levels beyond prior doses. T-cell responses remained stable and unenhanced by additional boosting, indicating potential for durable cellular protection despite low or waning antibody levels.
引用
- Ekström N, Liedes O, Vara S, et al. Immune responses following sequential mRNA booster doses targeting the SARS-CoV-2 omicron variants in immunocompromised individuals - A 3.5-year follow-up. Vaccine. 2026. PMID: 41740459. doi:10.1016/j.vaccine.2026.128347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。